References
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
- Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35:S109-14. https://doi.org/10.1097/00004836-200211002-00007
- Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 2017;9:907-20. https://doi.org/10.4254/wjh.v9.i21.907
- Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008;8:438-49. https://doi.org/10.1038/nrc2396
- Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000;19:2069-81. https://doi.org/10.1093/emboj/19.9.2069
- Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009;137:1816-26.e1-10. https://doi.org/10.1053/j.gastro.2009.08.005
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53. https://doi.org/10.1182/blood-2004-08-3097
- Salesse S, Verfaillie CM. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 2002;21:8547-59. https://doi.org/10.1038/sj.onc.1206082
- Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2:95-102. https://doi.org/10.1038/nchembio760
- Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004;15:405-9. https://doi.org/10.1097/00001813-200404000-00014
- Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008;10:e19. https://doi.org/10.1017/S1462399408000744
- Tsatsanis C, Spandidos DA. The role of oncogenic kinases in human cancer (Review). Int J Mol Med 2000;5:583-90.
- Paul MK, Mukhopadhyay AK. Tyrosine kinase: role and significance in cancer. Int J Med Sci 2004;1:101-15.
- Hassan AQ, Sharma SV, Warmuth M. Allosteric inhibition of BCR-ABL. Cell Cycle 2010;9:3710-4.
- Keshavarz-Pakseresht B, Shandiz SA, Baghbani-Arani F. Imatinib induces up-regulation of NM23, a metastasis suppressor gene, in human Hepatocarcinoma (HepG2) cell line. Gastroenterol Hepatol Bed Bench 2017;10:29-33.
- Mitupatum T, Aree K, Kittisenachai S, Roytrakul S, Puthong S, Kangsadalampai S, et al. Hep88 mAb-mediated paraptosis-like apoptosis in HepG2 cells via downstream upregulation and activation of caspase-3, caspase-8 and caspase-9. Asian Pac J Cancer Prev 2015;16:1771-9. https://doi.org/10.7314/APJCP.2015.16.5.1771
- Ramirez-Tagle R, Escobar CA, Romero V, Montorfano I, Armisen R, Borgna V, et al. Chalcone-induced apoptosis through caspase-dependent intrinsic pathways in human hepatocellular carcinoma cells. Int J Mol Sci 2016;17:260. https://doi.org/10.3390/ijms17020260
- Wei Z, Jiang X, Qiao H, Zhai B, Zhang L, Zhang Q, et al. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal 2013;25:931-8. https://doi.org/10.1016/j.cellsig.2013.01.011
- Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 2015;21:12150-6. https://doi.org/10.3748/wjg.v21.i42.12150
- Auld CA, Caccia CD, Morrison RF. Hormonal induction of adipogenesis induces Skp2 expression through PI3K and MAPK pathways. J Cell Biochem 2007;100:204-16. https://doi.org/10.1002/jcb.21063
- Bu W, Luo T. miR-1297 Promotes cell proliferation of non-small cell lung cancer cells: involving in PTEN/Akt/Skp2 signaling pathway. DNA Cell Biol 2017;36:976-82. https://doi.org/10.1089/dna.2017.3886
- Liu X, Wang H, Ma J, Xu J, Sheng C, Yang S, et al. The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation. Med Oncol 2013;30:735. https://doi.org/10.1007/s12032-013-0735-0
- Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005;65:3264-72. https://doi.org/10.1158/0008-5472.CAN-04-1357